For aseptic injectable preparation, Irinotecan Hydrochloride Pharma Grade API is dissolved in cold Water for Injection to a concentration of 20 mg/mL with sorbitol USP as tonicity modifier and lactic acid NF as the acidic vehicle. The manufacturing pH is locked between pH 3.0 and pH 3.8, nominally pH 3.5, because the closed-ring lactone form of irinotecan remains dominant only under acidic conditions. Above pH 6.0 the lactone opens to the carboxylate form, which exhibits lower antineoplastic activity and different plasma protein binding. The solution is sterile-filtered through a 0.22 μm PVDF or PES sterilising-grade membrane into sterile Type I borosilicate glass vials under ISO 5 conditions within an ISO 7 aseptic filling suite. Terminal steam sterilisation is avoided due to heat-accelerated hydrolysis of the lactone ring. In-process controls include pH by Ph Eur 2.2.3, osmolality, sub-visible particulate count per USP <788>, visible particles per USP <790>, bacterial endotoxins per USP <85>, and sterility per USP <71>. Filter integrity is verified by bubble point before and after filling. The batch record must include a media fill qualification in accordance with PDA Technical Report 22 and a bioburden limit for the pre-filtration solution. Because the drug substance is handled as a hazardous cytotoxic agent, powder charging and liquid transfer are performed in a negative-pressure isolator or closed-system transfer device per USP <800> and NIOSH Alert guidelines. The viscosity of the 20 mg/mL solution is low, so the filling nozzle diameter and line speed are set to prevent foaming and splashing rather than to manage high back-pressure. Modification of the tonicity agent requires a forced degradation study under ICH Q1A(R2) and ICH Q1B to verify that the lactone equilibrium is not shifted.

What Limits Diluted Infusion Hold Times in Centralised Cytotoxic Compounding Units?

Preparation of FOLFIRI and similar regimens requires dilution of the concentrated injection into 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP to a final concentration of 0.12 mg/mL to 2.8 mg/mL. The diluted infusion is stored in non-PVC, non-DEHP containers and administered through compatible administration sets because the acidic vehicle may extract plasticizer from flexible PVC and because the drug is a known hazardous drug requiring closed-system handling. The maximum hold time of 24 h at either 2–8°C or 15–30°C is derived from the approved labelling for irinotecan hydrochloride injection; exposure to direct sunlight or elevated temperature accelerates degradation to SN-38 carboxylate. In the compounding suite, the responsible pharmacist must document the beyond-use date according to USP <797> for low-risk compounded sterile preparations, but the chemical stability limit of 24 h takes precedence when shorter than the default USP <797> limit. Physical compatibility with 5-fluorouracil and leucovorin in the same infusion line is regimen-specific. Published compatibility data for undiluted admixtures is limited, and line separation or sequential flushing with 0.9% sodium chloride is required unless site-specific stability data exist. The pH of the final admixture must be checked and recorded because diluents with higher pH can reduce the lactone fraction before administration. A refrigerated admixture is brought to room temperature before administration only if precipitation or crystallization is absent; precipitation can occur if the solution pH is inadvertently adjusted above pH 6.0 or if potassium-containing diluents are used. Filtration of the diluted admixture through a 0.2 μm or 5 μm in-line filter is acceptable only if the filter membrane is tested for drug binding at low concentration.

Lyophilised Cake Design and Cryoprotectant Selection for Irinotecan Hydrochloride

Lyophilisation is selected when shelf-life robustness or reduced aqueous headspace reaction is required. The formulation is typically a mannitol-based matrix at pH 3.0–3.5, with the API dissolved as a 20 mg/mL liquid before freezing. The freeze-drying cycle is developed by freeze-drying microscopy and differential scanning calorimetry to avoid collapse above the collapse temperature of the partially crystalline mannitol phase. A typical cycle may include cooling of filled vials to −40°C, primary drying at shelf temperatures between −20°C and −10°C under vacuum, and secondary drying at +25°C to +35°C until the residual moisture is below 1.0% by Karl Fischer titration. Thermal cycling must not raise the product temperature above the glass transition temperature of the maximally freeze-concentrated solute, otherwise microcollapse occurs and the cake loses mechanical strength. The reconstituted solution must meet the same pH, osmolality, particulate, potency, and impurity specifications as the liquid concentrate; the USP monograph chromatographic method is used to quantify total impurities and SN-38 carboxylate content. Vial closure integrity is verified by dye ingress or vacuum decay per USP <1207> after the lyophilisation chamber is stoppered under partial vacuum or nitrogen. The stopper must be a fluoropolymer-coated elastomer because the low-pH formulation can generate volatile silicone oligomer leachables from uncoated stoppers. Because the drug substance is light-sensitive, the lyophilised cake is filled and stored in amber or opaque vials or secondary cartons that block light transmission below 1.0% in the 320–400 nm range according to ICH Q1B.

Oral Capsule Development Cannot Ignore the pH-Dependent Lactone Ring Equilibrium

Preformulation for hard gelatin or hypromellose capsule filling begins with quantification of the intact lactone fraction in simulated gastric fluid at 37°C, pH 1.2, and in phosphate buffer at pH 6.8. Irinotecan hydrochloride is freely soluble in acidic aqueous media but less soluble in neutral buffers; therefore, a pH-modifying acidulant may be required in the capsule fill only if the dissolution method demands rapid release in the stomach. A typical dry-mix capsule formulation includes lactose monohydrate as the diluent, croscarmellose sodium as the disintegrant, colloidal silicon dioxide as the glidant, and magnesium stearate as the lubricant. The lubricant is added at the final blending step for 3 to 5 minutes because overmixing can cause hydrophobic film formation on particle surfaces and slow dissolution. Blend uniformity is tested according to USP <905> or Ph Eur 2.9.40, and acceptance criteria for the API are based on a relative standard deviation not exceeding 5.0% unless the marketed product specification justifies a wider limit. The capsule fill weight is controlled to ±2.0% of target on an automatic dosator or tamping-pin encapsulation machine. Moisture control is critical because the hydrochloride salt is hygroscopic and because free water accelerates ring opening to the carboxylate; the empty capsule shell moisture content should be below 15.0% for gelatin and below 6.0% for HPMC at the time of filling. Environmental relative humidity is maintained below 35% RH when the API is exposed during weighing and blending. Dissolution testing uses USP <711> Apparatus II at 50 rpm in 900 mL of 0.1 N hydrochloric acid at 37°C for the immediate-release specification, with the acceptance level Q = 80% at 45 minutes unless the registered monograph declares otherwise. Published clinical data for an immediate-release oral irinotecan capsule are limited; the formulation parameters above reflect standard preformulation and USP general chapter techniques rather than an approved commercial oral product.

When Dose-Adapted Granules Require a Dry Granulation Route Instead of Aqueous Wet Massing

Oral granules or sachet presentations are used when dose adaptation is required for body surface area protocols, swallowing difficulty, or enteral tube administration. Aqueous high-shear granulation is generally avoided because the added water at the surface of the drug particles creates a local pH environment in which the lactone ring can open, leading to variable potency and an increase in the carboxylate impurity. Dry granulation by roller compaction is preferred: the API is pre-blended with microcrystalline cellulose and crospovidone, compacted at a roll pressure of 20 to 40 kN, and milled through a 1.0 mm screen to obtain a free-flowing granule. The binder is either dry starch or pregelatinized starch, because these materials have low residual water and do not require aqueous dissolution. Granule moisture is controlled below 3.0% by loss on drying, and water activity is measured at 25°C to remain below 0.6. Granule flow is characterized by USP <1174> powder flow or Ph Eur 2.9.36, and the final sachet fill is checked for uniformity of mass per USP <905>. Enteric coating of irinotecan granules is not recommended without dedicated stability data because the delayed-release coat would expose the drug to intestinal pH above pH 6.8, where the carboxylate form predominates and the desired exposure profile may not be achieved. If enteric delivery is investigated, the coating polymer should be HPMC acetate succinate or methacrylic acid copolymer dispersion applied in a fluid-bed coater with an inlet air temperature below 45°C to limit thermal hydrolysis. Published data for this specific irinotecan granule configuration is limited; the process above is based on general oral cytotoxic granulation practice and ICH Q6A decision-tree logic for immediate-release solid oral dosage forms.

In a dry compression suite, the direct-compression blend for irinotecan hydrochloride tablets is pre-sieved through a 40-mesh screen before dry mixing with mannitol or microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate, and fumed silica. The compression blend is lubricated with 0.5% to 1.0% w/w magnesium stearate in a bin blender at 10 to 15 rpm for no more than 5 minutes. Tablets are compressed on a rotary tablet press with a compression force between 8 kN and 20 kN to achieve a hardness of 60 N to 100 N and a friability below 1.0% per USP <1216>. The tablet press is installed in a containment isolator with negative air pressure to limit operator exposure to cytotoxic dust. The compression speed is reduced to 30 to 50 rpm to control punch sticking, which is observed when the blend moisture exceeds 1.5% or when the lubricant is overmixed. Tablet weight, thickness, hardness, disintegration time per USP <701>, and content uniformity per USP <905> are tested in-process. The disintegration specification for immediate-release tablets is not more than 15 minutes in water at 37°C. Dissolution testing follows USP <711> with acid medium; if the tablet formulation contains an alkalizing excipient, dissolution in pH 6.8 buffer must be added because the lactone-to-carboxylate transition can produce a falsely low extraction of intact drug. The finished tablet is packaged in aluminium-aluminium blisters or HDPE bottles with a desiccant to maintain moisture below the threshold that triggers ring opening. Batch stability is assessed under ICH Q1A(R2) conditions of 25°C/60% RH and 40°C/75% RH, with HPLC purity testing for total impurities, SN-38 carboxylate, and dissolution profile comparison according to ICH Q2(R1) and Ph Eur 2.2.46.